Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.62 Insider Own1.20% Shs Outstand182.70M Perf Week-5.55%
Market Cap2.96B Forward P/E- EPS next Y-2.18 Insider Trans-7.15% Shs Float182.10M Perf Month-11.43%
Income-474.30M PEG- EPS next Q-0.80 Inst Own92.60% Short Float8.89% Perf Quarter0.68%
Sales105.50M P/S28.09 EPS this Y1.20% Inst Trans-0.00% Short Ratio18.94 Perf Half Y-19.81%
Book/sh4.95 P/B3.30 EPS next Y27.70% ROA-32.30% Target Price- Perf Year-4.83%
Cash/sh5.52 P/C2.96 EPS next 5Y-7.30% ROE-45.70% 52W Range12.92 - 26.75 Perf YTD-3.82%
Dividend- P/FCF- EPS past 5Y-32.40% ROI-39.50% 52W High-38.88% Beta1.23
Dividend %- Quick Ratio7.90 Sales past 5Y-7.90% Gross Margin77.90% 52W Low26.55% ATR0.67
Employees718 Current Ratio8.10 Sales Q/Q-42.00% Oper. Margin- RSI (14)45.07 Volatility3.41% 3.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-53.10% Profit Margin- Rel Volume0.48 Prev Close16.56
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume855.15K Price16.35
Recom2.20 SMA20-5.88% SMA501.04% SMA200-10.57% Volume406,781 Change-1.27%
Sep-10-21Initiated BofA Securities Neutral $18
Jun-28-21Upgrade Stifel Hold → Buy $22 → $24
May-18-21Resumed Goldman Neutral $24
Feb-22-21Downgrade The Benchmark Company Buy → Hold
Jan-06-21Initiated Stifel Hold $18
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Sep-22-21 11:09AM  
Sep-21-21 11:02AM  
09:00AM  
Sep-13-21 11:47AM  
Sep-02-21 12:03PM  
Aug-06-21 12:31PM  
Aug-05-21 09:31PM  
05:45PM  
04:15PM  
Jul-29-21 03:05PM  
Jul-27-21 06:00PM  
Jul-26-21 05:09PM  
Jul-19-21 09:00AM  
Jun-07-21 08:30AM  
Jun-04-21 10:46AM  
May-27-21 06:36AM  
May-20-21 11:00AM  
May-18-21 08:00AM  
May-10-21 03:09AM  
May-07-21 03:30AM  
May-06-21 05:45PM  
04:15PM  
Apr-29-21 12:34PM  
Apr-27-21 06:00PM  
Mar-27-21 11:31AM  
Feb-26-21 09:09AM  
07:20AM  
03:11AM  
01:01AM  
Feb-25-21 05:10PM  
03:15PM  
Feb-18-21 05:30PM  
Feb-17-21 04:19PM  
09:25AM  
08:00AM  
07:59AM  
Feb-08-21 07:19AM  
Jan-24-21 06:08AM  
Jan-06-21 05:00PM  
07:30AM  
Jan-05-21 04:20PM  
Dec-22-20 11:03AM  
08:30AM  
Dec-18-20 08:15PM  
Dec-16-20 10:45AM  
Dec-15-20 08:30AM  
Dec-08-20 06:00AM  
Dec-07-20 04:00PM  
Dec-05-20 11:32AM  
Nov-11-20 02:00PM  
Nov-10-20 06:47AM  
Nov-09-20 09:04AM  
Nov-06-20 02:01AM  
Nov-05-20 08:00PM  
04:15PM  
04:00PM  
Nov-04-20 10:15AM  
Oct-29-20 06:00PM  
12:34PM  
Oct-28-20 06:00PM  
12:32PM  
Oct-27-20 07:30AM  
Oct-05-20 03:27PM  
Sep-28-20 05:24PM  
Sep-24-20 06:47PM  
Sep-05-20 11:32AM  
Aug-12-20 09:42AM  
08:00AM  
Aug-07-20 11:35AM  
Aug-06-20 07:00PM  
04:15PM  
Aug-05-20 11:15AM  
Jul-30-20 12:33PM  
Jul-28-20 06:00PM  
Jun-23-20 09:46PM  
Jun-14-20 09:25PM  
Jun-06-20 11:31AM  
Jun-04-20 05:00PM  
May-29-20 05:00PM  
May-26-20 11:11AM  
May-22-20 08:30AM  
May-18-20 08:05AM  
May-17-20 07:13PM  
May-12-20 06:27AM  
May-08-20 10:29AM  
03:57AM  
03:31AM  
May-07-20 05:55PM  
04:15PM  
Apr-30-20 12:33PM  
Apr-28-20 05:00PM  
Apr-09-20 06:08PM  
Apr-06-20 06:24AM  
Mar-29-20 10:51PM  
Mar-28-20 11:30AM  
Mar-11-20 09:19PM  
Mar-01-20 09:15AM  
Feb-28-20 06:30PM  
08:15AM  
04:39AM  
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curet MyriamDirectorSep 22Sale17.783,66565,16425,775Sep 24 06:14 PM
CHESS ROBERTDirectorSep 22Sale17.944,60082,524279,873Sep 24 06:13 PM
Ajer Jeffrey RobertDirectorSep 22Sale17.783,66565,16432,510Sep 24 06:12 PM
WHITFIELD ROY ADirectorSep 16Option Exercise13.8040,000552,000225,850Sep 17 06:44 PM
CHESS ROBERTDirectorSep 09Option Exercise13.8010,279141,850284,552Sep 10 06:03 PM
CHESS ROBERTDirectorSep 09Sale16.0210,279164,670274,273Sep 10 06:03 PM
CHESS ROBERTDirectorSep 08Option Exercise13.808,000110,400282,273Sep 10 06:03 PM
CHESS ROBERTDirectorSep 08Sale16.008,000128,000274,273Sep 10 06:03 PM
GREER R SCOTTDirectorAug 31Option Exercise12.7045,000571,500270,674Aug 31 06:26 PM
Labrucherie Gil MSVP, COO & CFOAug 17Sale13.563,00040,680240,231Aug 18 06:58 PM
Zalevsky JonathanChief R&D OfficerAug 16Sale13.837,662105,965212,803Aug 18 07:04 PM
Wilson Mark AndrewSVP & General CounselAug 16Sale13.831,91026,41572,900Aug 18 07:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale13.8313,339184,478137,822Aug 18 07:00 PM
ROBIN HOWARD WPresident & CEOAug 16Sale13.8311,515159,252424,123Aug 18 07:01 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerAug 16Sale13.836,19285,635200,915Aug 18 06:59 PM
Labrucherie Gil MSVP, COO & CFOAug 16Sale13.837,867108,801243,231Aug 18 06:58 PM
CHESS ROBERTDirectorJul 22Option Exercise13.80911,256280,664Jul 22 07:13 PM
CHESS ROBERTDirectorJul 22Sale16.80911,529280,573Jul 22 07:13 PM
CHESS ROBERTDirectorJul 21Option Exercise13.803,52448,631284,097Jul 22 07:13 PM
CHESS ROBERTDirectorJul 21Sale16.813,52459,238280,573Jul 22 07:13 PM
CHESS ROBERTDirectorJul 20Option Exercise13.802,10629,063282,679Jul 22 07:13 PM
CHESS ROBERTDirectorJul 20Sale16.802,10635,381280,573Jul 22 07:13 PM
Wilson Mark AndrewSVP & General CounselMay 17Sale18.301,91735,08174,810May 19 07:07 PM
Zalevsky JonathanChief R&D OfficerMay 17Sale18.3031,111569,331235,065May 19 07:08 PM
ROBIN HOWARD WPresident & CEOMay 17Sale18.3011,560211,548435,638May 19 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 17Sale18.3013,391245,055151,161May 19 07:06 PM
Labrucherie Gil MSVP, COO & CFOMay 17Sale18.307,898144,533251,098May 19 07:04 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerMay 17Sale18.306,085111,356207,107May 19 07:04 PM
CHESS ROBERTDirectorMay 12Option Exercise13.808,000110,400288,573May 14 06:05 PM
CHESS ROBERTDirectorMay 12Sale19.348,000154,720280,573May 14 06:05 PM
CHESS ROBERTDirectorApr 14Option Exercise13.808,000110,400288,573Apr 16 06:02 PM
CHESS ROBERTDirectorApr 14Sale18.988,000151,840280,573Apr 16 06:02 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale22.3724,141540,034266,176Feb 18 07:07 PM
Wilson Mark AndrewSVP & General CounselFeb 16Sale22.372,17348,61076,727Feb 18 07:06 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale22.3711,705261,841164,552Feb 18 07:05 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerFeb 16Sale22.3715,358343,558213,192Feb 18 07:03 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale22.3711,495257,143447,198Feb 18 07:04 PM
Labrucherie Gil MSVP, COO & CFOFeb 16Sale22.377,977178,445258,996Feb 18 07:03 PM
Labrucherie Gil MSVP, COO & CFOFeb 04Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 04Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
ROBIN HOWARD WPresident & CEOFeb 04Sale20.29150,0003,042,906458,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 04Sale19.8150,000990,500266,973Feb 04 08:42 PM
Labrucherie Gil MSVP, COO & CFOFeb 03Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 03Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
Wilson Mark AndrewSVP & General CounselFeb 03Sale19.455,344103,94178,900Feb 04 08:44 PM
ROBIN HOWARD WPresident & CEOFeb 03Sale19.72150,0002,958,000458,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 03Sale19.6150,000980,500266,973Feb 04 08:42 PM
Labrucherie Gil MSVP, COO & CFOFeb 02Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 02Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
ROBIN HOWARD WPresident & CEOFeb 02Sale19.77150,0002,966,025458,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 02Sale20.1750,0001,008,629266,973Feb 04 08:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJan 28Option Exercise8.8075,000660,000251,257Jan 29 06:10 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJan 28Sale18.6275,0001,396,500176,257Jan 29 06:10 PM
GREER R SCOTTDirectorJan 05Option Exercise13.8040,000552,000225,674Jan 05 05:09 PM
Myriam CuretDirectorDec 15Sale17.821,56027,79919,240Dec 17 06:08 PM
Zalevsky JonathanChief R&D OfficerNov 23Sale16.4016,380268,632250,317Nov 25 06:09 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale16.9329,618501,433266,697Nov 18 07:08 PM
Wilson Mark AndrewSVP & General CounselNov 16Sale16.931,53926,05549,850Nov 18 07:07 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale16.9311,976202,754159,757Nov 18 07:05 PM
ROBIN HOWARD WPresident & CEONov 16Sale16.9311,975202,737352,043Nov 18 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 16Sale16.938,276140,113226,973Nov 18 07:03 PM